{
  "experiment_id": "aa7227018343fa2a5f6df22ada9bd727",
  "task_name": "narrowing_of_broad_synonyms",
  "task_hash": "9dc5c284f909400a12e111d9ec8ba4e5",
  "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
  "system_instructions": "You are a metadata curation assistant. Your task is to help improve and correct metadata \naccording to the specific instructions provided for each task. Be precise, accurate, and \nfollow the guidelines carefully.\n",
  "temperature": 0.0,
  "thinking": true,
  "timestamp": "2025-11-13T05:47:00.975945",
  "task_result": {
    "task_name": "narrowing_of_broad_synonyms",
    "num_samples": 10,
    "results": [
      {
        "sample_index": 0,
        "input": {
          "diagnosis": "Neurofibromatosis",
          "assay": "DNA sequencing",
          "tumorType": "Neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Plexiform Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: Narrowed \"Neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" (the most common and specific form)\n\n2. **assay**: Narrowed \"DNA sequencing\" \u2192 \"whole exome sequencing\" (a specific, commonly used DNA sequencing method for genetic diagnosis)\n\n3. **tumorType**: Narrowed \"Neurofibroma\" \u2192 \"Plexiform Neurofibroma\" (a specific, clinically significant subtype of neurofibroma commonly associated with NF1)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3058,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1283
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01HMKkMkYvD5inCzhTaNeuRt",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad terms to more specific terms from the Target Schema's controlled terminology.\n\nInput:\n- \"diagnosis\": \"Neurofibromatosis\"\n- \"assay\": \"DNA sequencing\"  \n- \"tumorType\": \"Neurofibroma\"\n\nLooking at the Target Schema:\n\n1. **diagnosis**: \"Neurofibromatosis\" is too broad. Looking at the enum values, I can see:\n   - \"Neurofibromatosis type 1\" - this is the specific type\n   - There's no \"Neurofibromatosis type 2\" but there is \"NF2-related schwannomatosis\"\n   \n   The most common form is NF1 (Neurofibromatosis type 1), which accounts for about 96% of all neurofibromatosis cases. So \"Neurofibromatosis\" should be narrowed to \"Neurofibromatosis type 1\".\n\n2. **assay**: \"DNA sequencing\" is too broad. Looking at the enum values for sequencing assays:\n   - \"whole genome sequencing\" - sequences the entire genome\n   - \"whole exome sequencing\" - sequences protein-coding regions\n   - \"targeted sequencing\" - sequences specific regions\n   - \"next generation targeted sequencing\" - more specific targeted sequencing\n   - \"RNA-seq\", \"bisulfite sequencing\", \"Sanger sequencing\", etc.\n   \n   \"DNA sequencing\" is a general term. The most common comprehensive DNA sequencing methods would be either:\n   - \"whole genome sequencing\" - for complete genome analysis\n   - \"whole exome sequencing\" - for coding region analysis\n   \n   Given that the context involves neurofibromatosis research, and without more specific information, \"whole exome sequencing\" is likely the most appropriate narrowing, as it's commonly used in clinical and research settings for genetic diagnosis. However, \"whole genome sequencing\" would also be reasonable. Let me consider which is more commonly used for NF1 diagnosis - typically whole exome sequencing is used initially for genetic testing, so I'll go with that. Actually, thinking about it more, if we're just narrowing from \"DNA sequencing\" without additional context, \"whole genome sequencing\" could be considered the most comprehensive narrowing. But \"whole exome sequencing\" is more commonly used in clinical practice for ne\n\nI'll select \"whole exome sequencing\" since it's the standard clinical approach for NF1 genetic testing.\n\n3. **tumorType**: \"Neurofibroma\" already appears in the enum list, but there are more specific subtypes available like \"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\", \"Localized Neurofibroma\", and \"Nodular Neurofibroma\".\n\nSince \"Neurofibroma\" needs narrowing and the most common types in NF1 are cutaneous and plexiform neurofibromas, I'm considering between these two. Cutaneous neurofibromas are more frequent, but plexiform neurofibromas carry greater clinical significance. Without additional clinical context, I'll choose based on clinical importance rather than frequency.\n\nI'm selecting \"Plexiform Neurofibroma\" as the narrowed term because of its clinical relevance in NF1 research and treatment, despite cutaneous being more common numerically.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Plexiform Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: Narrowed \"Neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" (the most common and specific form)\n\n2. **assay**: Narrowed \"DNA sequencing\" \u2192 \"whole exome sequencing\" (a specific, commonly used DNA sequencing method for genetic diagnosis)\n\n3. **tumorType**: Narrowed \"Neurofibroma\" \u2192 \"Plexiform Neurofibroma\" (a specific, clinically significant subtype of neurofibroma commonly associated with NF1)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3058,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1283
            }
          }
        },
        "score": 1.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Plexiform Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3058,
          "output_tokens": 1283,
          "total_tokens": 4341
        }
      },
      {
        "sample_index": 1,
        "input": {
          "diagnosis": "NF",
          "assay": "exome sequencing",
          "tumorType": "sarcoma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}\n```\n\n**Changes made:**\n- **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" (narrowed the abbreviation to the full, specific diagnosis name)\n- **assay**: \"exome sequencing\" \u2192 \"whole exome sequencing\" (narrowed to the complete technical term as specified in the controlled vocabulary)\n- **tumorType**: \"sarcoma\" \u2192 \"Sarcoma\" (corrected to match the exact controlled terminology value with proper capitalization)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3052,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 791
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_015kCDsykAEHta8Qzd7dG9Sg",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad synonyms according to the Target Schema:\n\n1. **diagnosis**: \"NF\" - This is very broad. Looking at the enum values, \"NF\" could refer to:\n   - \"Neurofibromatosis type 1\" (NF1)\n   - \"NF2-related schwannomatosis\" (NF2)\n   \n   However, \"NF\" is most commonly used to refer to Neurofibromatosis type 1, as this is the most common form. But I need to be careful here. Looking at the context, there's a \"sarcoma\" mentioned in tumorType, and NF1 is commonly associated with various tumors including sarcomas (MPNST). Without more context, \"NF\" most likely refers to \"Neurofibromatosis type 1\" which is the most common neurofibromatosis.\n\n2. **assay**: \"exome sequencing\" - Looking at the enum values, I can see:\n   - \"whole exome sequencing\"\n   \n   \"exome sequencing\" is clearly referring to \"whole exome sequencing\" which is the standard term for this technique.\n\n3. **tumorType**: \"sarcoma\" - This is broad. Looking at the enum values, I can see:\n   - \"Sarcoma\" (this is actually in the enum!)\n   - \"Fibrosarcoma\"\n   - \"Malignant Peripheral Nerve Sheath Tumor\" (which is a type of sarcoma)\n   \n   Wait, \"Sarcoma\" is actually an exact value in the enum! So I should use \"Sarcoma\" with the capital S to match exactly.\n\nLet me reconsider:\n- diagnosis: \"NF\" \u2192 \"Neurofibromatosis type 1\" (most common interpretation)\n- assay: \"exome sequencing\" \u2192 \"whole exome sequencing\"\n\n\n- tumorType: \"sarcoma\" \u2192 \"Sarcoma\"\n\nI'll stick with the exact enum value \"Sarcoma\" since there's insufficient context to justify a more specific classification. The controlled terminology requires using the precise match from the Target Schema.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}\n```\n\n**Changes made:**\n- **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" (narrowed the abbreviation to the full, specific diagnosis name)\n- **assay**: \"exome sequencing\" \u2192 \"whole exome sequencing\" (narrowed to the complete technical term as specified in the controlled vocabulary)\n- **tumorType**: \"sarcoma\" \u2192 \"Sarcoma\" (corrected to match the exact controlled terminology value with proper capitalization)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3052,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 791
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3052,
          "output_tokens": 791,
          "total_tokens": 3843
        }
      },
      {
        "sample_index": 2,
        "input": {
          "diagnosis": "Neurofibromatoses",
          "assay": "assay by high throughput sequencer",
          "tumorType": "Nerve Sheath Neoplasm"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Narrowing rationale:**\n- **diagnosis**: \"Neurofibromatoses\" (broad plural term) \u2192 \"Neurofibromatosis type 1\" (most common specific neurofibromatosis condition)\n- **assay**: \"assay by high throughput sequencer\" (broad method description) \u2192 \"whole genome sequencing\" (specific high-throughput sequencing assay)\n- **tumorType**: \"Nerve Sheath Neoplasm\" (broad pathological category) \u2192 \"Neurofibroma\" (specific nerve sheath tumor type commonly associated with neurofibromatosis)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3067,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1222
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01TC155GMSnJXu4CUPmaa9iM",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "I need to analyze the input data and narrow the broad terms to specific controlled terminology values from the Target Schema.\n\nLet me examine each field:\n\n1. **diagnosis**: \"Neurofibromatoses\"\n   - This is a broad term referring to neurofibromatosis conditions\n   - Looking at the enum options, I can see:\n     - \"Neurofibromatosis type 1\"\n     - \"NF2-related schwannomatosis\"\n     - Various schwannomatosis types\n   - \"Neurofibromatoses\" is the plural, general term for the group of conditions\n   - The most common and likely specific match would be \"Neurofibromatosis type 1\" (NF1), which is the most prevalent form\n   - However, without additional context, I could also consider \"Schwannomatosis\" or other specific types\n   - Given that NF1 is the most common neurofibromatosis (occurring in about 1 in 3,000 births), and when people refer to \"neurofibromatoses\" in general, NF1 is often what they mean, I'll narrow it to \"Neurofibromatosis type 1\"\n\n2. **assay**: \"assay by high throughput sequencer\"\n   - This is clearly referring to high-throughput sequencing\n   - Looking at sequencing-related options in the enum:\n     - \"whole genome sequencing\"\n     - \"whole exome sequencing\"\n     - \"RNA-seq\"\n     - \"targeted sequencing\"\n     - \"next generation targeted sequencing\"\n     - \"bisulfite sequencing\"\n     - Various other specific sequencing methods\n   - \"assay by high throughput sequencer\" is a broad term that could refer to any NGS method\n   - Without more specific context, the most general high-throughput sequencing would be \"whole genome sequencing\" or \"RNA-seq\"\n   - However, \"whole genome sequencing\" is a more comprehensive and commonly used high-throughput sequencing method\n   - I'll choose \"whole genome sequencing\" as it's the broadest form of high-throughput sequencing\n\n3. **tumorType**: \"Nerve Sheath Neoplasm\"\n   - This is a broad term for tumors of nerve sheath origin\n   - Looking at the enum options, I see potential matches like \"Malignant Peripheral Nerve Sheath Tumor\" (MPNST), \"Schwannoma\", and \"Neurofibroma\"\n   - \"Nerve Sheath Neoplasm\" encompasses all these specific tumor types\n   - Considering the context of neurofibromatosis, \"Neurofibroma\" seems the most appropriate specific classification\n   - Neurofibromas are characteristic tumors in neurofibromatosis, particularly in NF1 patients\n   - I'll map this to \"Neurofibroma\" as the most precise representation of the broad \"Nerve Sheath Neoplasm\" category I'm focusing on narrowing broad medical terms to their most specific diagnostic representations. For neurofibromatosis, I'll select \"Neurofibromatosis type 1\" as the precise diagnosis, given its prevalence. In genomic analysis, \"whole genome sequencing\" provides comprehensive genetic insights. For the tumor classification, \"Neurofibroma\" emerges as the most appropriate nerve sheath neoplasm, particularly characteristic of NF1. These targeted selections reflect careful clinical reasoning, prioritizing specificity and diagnostic accuracy.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Narrowing rationale:**\n- **diagnosis**: \"Neurofibromatoses\" (broad plural term) \u2192 \"Neurofibromatosis type 1\" (most common specific neurofibromatosis condition)\n- **assay**: \"assay by high throughput sequencer\" (broad method description) \u2192 \"whole genome sequencing\" (specific high-throughput sequencing assay)\n- **tumorType**: \"Nerve Sheath Neoplasm\" (broad pathological category) \u2192 \"Neurofibroma\" (specific nerve sheath tumor type commonly associated with neurofibromatosis)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3067,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1222
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole genome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3067,
          "output_tokens": 1222,
          "total_tokens": 4289
        }
      },
      {
        "sample_index": 3,
        "input": {
          "diagnosis": "neurocutaneous syndrome",
          "assay": "spectroscopy",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"FTIR spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"neurocutaneous syndrome\" \u2192 \"Unknown\"\n   - \"Neurocutaneous syndrome\" is a broad umbrella term that could refer to several conditions in the schema (Neurofibromatosis type 1, NF2-related schwannomatosis, various Schwannomatosis types, etc.). Without additional context to specify which particular syndrome, the most appropriate narrowing is \"Unknown\".\n\n2. **assay**: \"spectroscopy\" \u2192 \"FTIR spectroscopy\"\n   - \"Spectroscopy\" is a broad analytical technique category. The schema contains specific spectroscopy methods: \"FTIR spectroscopy\" and \"magnetic resonance spectroscopy\". FTIR spectroscopy is a commonly used analytical technique in biomedical research for chemical characterization.\n\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\"\n   - Corrected to match the exact controlled terminology with proper capitalization as specified in the schema enum.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3052,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1020
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01PxpiumN8FXrxDamNVQc6t9",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze each field in the input data and narrow it to the appropriate controlled terminology from the Target Schema:\n\n1. **diagnosis**: \"neurocutaneous syndrome\"\n   - This is a broad term that refers to conditions affecting both the nervous system and skin\n   - Looking at the enum values, the neurocutaneous syndromes in the list include:\n     - \"Neurofibromatosis type 1\" (NF1)\n     - \"NF2-related schwannomatosis\"\n     - \"Schwannomatosis\" (and its variants)\n     - \"Noonan Syndrome\"\n   - Since \"neurocutaneous syndrome\" is a general term and we need to narrow it, but we don't have specific information to determine which one, the most appropriate choice would be \"Unknown\" since we cannot definitively narrow it to a specific condition without more context.\n   - Wait, let me reconsider - the task is to narrow broad synonyms. \"unknown\" in the input is already a value, but lowercase. Looking at the enum, there is \"Unknown\" with capital U.\n\n2. **assay**: \"spectroscopy\"\n   - This is a broad term for analytical techniques\n   - Looking at the enum values, I can see specific types of spectroscopy:\n     - \"FTIR spectroscopy\" (Fourier Transform Infrared Spectroscopy)\n     - \"magnetic resonance spectroscopy\"\n   - Since \"spectroscopy\" is too broad and could refer to either of these or other types, but we don't have enough context, we might need to pick the most general match or \"Unknown\" isn't in the assay enum. Looking more carefully, there's no \"Unknown\" value in the assay enum.\n   - Actually, looking at the values more carefully, \"spectroscopy\" could be narrowed to \"FTIR spectroscopy\" or \"magnetic resonance spectroscopy\". Without more context, I should probably choose the most commonly used one in biomedical research contexts, which would likely be \"magnetic resonance spectroscopy\" for in vivo studies or \"FTIR spectroscopy\" for material/chemical analysis.\n   - For metadata curation, I'll select \"FTIR spectroscopy\" as a precise analytical technique that narrows the broad term effectively.\n\n3. **tumorType**: \"unknown\"\n   - This should be narrowed to \"Unknown\" (with capital U) which is in the enum\n\nI'll focus on the neurocutaneous syndrome category, which encompasses several specific genetic conditions. The most appropriate approach is to select a precise term that captures the broad syndrome's characteristics.\n\nGiven the limited context, \"Unknown\" represents the most responsible diagnostic classification, avoiding unwarranted assumptions about the specific syndrome variant.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"FTIR spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"neurocutaneous syndrome\" \u2192 \"Unknown\"\n   - \"Neurocutaneous syndrome\" is a broad umbrella term that could refer to several conditions in the schema (Neurofibromatosis type 1, NF2-related schwannomatosis, various Schwannomatosis types, etc.). Without additional context to specify which particular syndrome, the most appropriate narrowing is \"Unknown\".\n\n2. **assay**: \"spectroscopy\" \u2192 \"FTIR spectroscopy\"\n   - \"Spectroscopy\" is a broad analytical technique category. The schema contains specific spectroscopy methods: \"FTIR spectroscopy\" and \"magnetic resonance spectroscopy\". FTIR spectroscopy is a commonly used analytical technique in biomedical research for chemical characterization.\n\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\"\n   - Corrected to match the exact controlled terminology with proper capitalization as specified in the schema enum."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3052,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1020
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 3052,
          "output_tokens": 1020,
          "total_tokens": 4072
        }
      },
      {
        "sample_index": 4,
        "input": {
          "diagnosis": "Not Applicable",
          "assay": "immunoassay",
          "tumorType": "neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"Not Applicable\" - Already matches the exact controlled terminology value from the schema. This is an appropriate specific term.\n\n2. **assay**: \"immunoassay\" - Already matches the exact controlled terminology value from the schema. While this is a broad category, it is a valid enum value and without additional context about the specific immunological technique used (immunocytochemistry, immunofluorescence, or immunohistochemistry), it remains as specified.\n\n3. **tumorType**: \"neurofibroma\" \u2192 **\"Neurofibroma\"** - Corrected capitalization to match the exact controlled terminology value from the schema. While there are more specific neurofibroma subtypes available (Cutaneous, Plexiform, Localized, etc.), \"Neurofibroma\" is the appropriate general term when the specific subtype is not known or specified.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3054,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1524
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_017EgwedJEZs5ajr8J6wWZxn",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and compare it to the Target Schema to narrow any broad terms to more specific ones.\n\nInput data:\n- diagnosis: \"Not Applicable\"\n- assay: \"immunoassay\"\n- tumorType: \"neurofibroma\"\n\nLooking at each field:\n\n1. **diagnosis**: \"Not Applicable\" \n   - This is already an exact match in the enum list. It's already specific.\n\n2. **assay**: \"immunoassay\"\n   - This is an exact match in the enum list, but it's a broad term. Let me check if there are more specific alternatives:\n   - The schema includes: \"immunoassay\", \"immunocytochemistry\", \"immunofluorescence\", \"immunohistochemistry\"\n   - \"immunoassay\" is indeed a broad term that encompasses various immunological assays\n   - However, without additional context about which specific type of immunoassay was used, I need to check if this should be narrowed\n   - The task says to \"narrow broad synonyms\" - but the issue is that \"immunoassay\" IS in the controlled vocabulary\n   - Looking at more specific immuno- terms: immunocytochemistry, immunofluorescence, immunohistochemistry are all more specific\n   - But I don't have information about which one to choose\n   - Wait, the instruction says: \"The input data contains metadata entries with broad, general terms that should be narrowed to more specific, precise terms.\"\n   - \"immunoassay\" is a general term, and there are more specific options available\n   - However, I cannot arbitrarily choose one without knowing which specific technique was used\n   - But let me re-read: \"you must use the exact controlled terminology values from the Target Schema provided below\"\n   - \"immunoassay\" IS in the controlled vocabulary, so it's valid\n   - But the task is to narrow broad terms when possible\n   \n3. **tumorType**: \"neurofibroma\"\n   - I notice multiple specific neurofibroma types in the schema\n   - The input uses a generic \"neurofibroma\" with lowercase spelling\n   - The schema offers precise subtypes like \"Atypical Neurofibroma\" and \"Cellular Neurofibroma\"\n   - Without additional context, I can't definitively choose a more specific subtype\n   - The exact match \"Neurofibroma\" exists in the schema with proper capitalization\n   - This suggests using the exact schema terminology is preferred I see several broad terms that need precise specification. The \"immunoassay\" could be narrowed to specific techniques like immunohistochemistry. For \"neurofibroma\", the schema suggests capitalizing the term and potentially selecting a more targeted subtype like plexiform or nodular neurofibroma. Case sensitivity matters here - matching the exact schema value is crucial. Without full clinical context, I'll focus on matching the schema's precise terminology while identifying opportunities for more specific classification. I'm considering the schema validation for these medical terms. The key is precise matching, especially for capitalization. \"Neurofibroma\" requires a capital N, while \"immunoassay\" seems technically valid but potentially broad. The diagnosis being \"Not Applicable\" suggests limited contextual details. Ensuring exact schema compliance means carefully checking each term's format and specificity.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"Not Applicable\" - Already matches the exact controlled terminology value from the schema. This is an appropriate specific term.\n\n2. **assay**: \"immunoassay\" - Already matches the exact controlled terminology value from the schema. While this is a broad category, it is a valid enum value and without additional context about the specific immunological technique used (immunocytochemistry, immunofluorescence, or immunohistochemistry), it remains as specified.\n\n3. **tumorType**: \"neurofibroma\" \u2192 **\"Neurofibroma\"** - Corrected capitalization to match the exact controlled terminology value from the schema. While there are more specific neurofibroma subtypes available (Cutaneous, Plexiform, Localized, etc.), \"Neurofibroma\" is the appropriate general term when the specific subtype is not known or specified."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3054,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1524
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Not Applicable",
          "assay": "immunohistochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3054,
          "output_tokens": 1524,
          "total_tokens": 4578
        }
      },
      {
        "sample_index": 5,
        "input": {
          "diagnosis": "neurofibromatosis",
          "assay": "plate based reporter assay",
          "tumorType": "benign neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"massively parallel reporter assay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n- **diagnosis**: \"neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" (narrowed to the most common specific form)\n- **assay**: \"plate based reporter assay\" \u2192 \"massively parallel reporter assay\" (narrowed to the specific reporter assay type in the controlled vocabulary)\n- **tumorType**: \"benign neurofibroma\" \u2192 \"Neurofibroma\" (narrowed to the specific controlled term; all neurofibromas in the schema are benign unless otherwise specified, so \"Neurofibroma\" is the appropriate specific term)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3060,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1141
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_013Vckyen3kBW6jjoDw9EXAB",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and match it with the Target Schema's controlled terminology:\n\n1. **diagnosis**: \"neurofibromatosis\"\n   - This is a broad term. Looking at the enum values, I can see:\n     - \"Neurofibromatosis type 1\"\n     - \"NF2-related schwannomatosis\"\n   - The most common form when just \"neurofibromatosis\" is mentioned is typically NF1 (Neurofibromatosis type 1), which is much more common than NF2.\n   - So \"neurofibromatosis\" should be narrowed to \"Neurofibromatosis type 1\"\n\n2. **assay**: \"plate based reporter assay\"\n   - This is a broad term. Looking at the enum values for assays, I need to find the most specific match.\n   - I can see \"massively parallel reporter assay\" in the list\n   - But \"plate based reporter assay\" could also be related to various high-throughput screening methods\n   - Looking at the options, \"massively parallel reporter assay\" is the most specific reporter assay type listed\n   - Another option could be \"high content screen\" or \"compound screen\" if it's a screening assay\n   - However, \"massively parallel reporter assay\" is the most specific match for a \"reporter assay\"\n\n3. **tumorType**: \"benign neurofibroma\"\n   - This is a broad term. Looking at the enum values:\n     - \"Neurofibroma\" (general)\n     - \"Cutaneous Neurofibroma\"\n     - \"Subcutaneous Neurofibroma\"\n     - \"Plexiform Neurofibroma\"\n     - \"Localized Neurofibroma\"\n     - \"Nodular Neurofibroma\"\n     - \"Cellular Neurofibroma\"\n     - \"Atypical Neurofibroma\"\n     - \"Diffuse Infiltrating Neurofibroma\"\n     - \"Massive Soft Tissue Neurofibroma\"\n     - \"Neurofibroma with Degenerative Atypia\"\n   \n   - \"benign neurofibroma\" is broad. The most common and general term from the list would be just \"Neurofibroma\" since all the other options are more specific subtypes. Since the input doesn't specify which subtype, \"Neurofibroma\" is the appropriate general category.\n\nActually, I'm reconsidering the task. It asks to narrow broad synonyms\u2014moving from general to specific. But without additional context about which subtype applies, I should use \"Neurofibroma\" as it's the base category. All the listed types are inherently benign anyway, so \"Neurofibroma\" captures the concept without overspecifying.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"massively parallel reporter assay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n- **diagnosis**: \"neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" (narrowed to the most common specific form)\n- **assay**: \"plate based reporter assay\" \u2192 \"massively parallel reporter assay\" (narrowed to the specific reporter assay type in the controlled vocabulary)\n- **tumorType**: \"benign neurofibroma\" \u2192 \"Neurofibroma\" (narrowed to the specific controlled term; all neurofibromas in the schema are benign unless otherwise specified, so \"Neurofibroma\" is the appropriate specific term)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3060,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1141
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "cell viability assay",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3060,
          "output_tokens": 1141,
          "total_tokens": 4201
        }
      },
      {
        "sample_index": 6,
        "input": {
          "diagnosis": "RASopathy",
          "assay": "immunoassay",
          "tumorType": "NFIB"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"RASopathy\" \u2192 \"Neurofibromatosis type 1\" \n   - \"RASopathy\" is a broad umbrella term for genetic syndromes affecting the RAS/MAPK pathway. Narrowed to \"Neurofibromatosis type 1\" as the most common NF-related RASopathy in this context.\n\n2. **assay**: \"immunoassay\" \u2192 \"immunoassay\"\n   - No change needed. This already matches the exact controlled terminology in the Target Schema.\n\n3. **tumorType**: \"NFIB\" \u2192 \"Neurofibroma\"\n   - \"NFIB\" appears to be an abbreviation or broad code. Narrowed to \"Neurofibroma\" as the appropriate specific tumor type from the controlled vocabulary.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3055,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1322
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01C3sRCAVEAFFR8qpbfWZetS",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Looking at the input data:\n- \"diagnosis\": \"RASopathy\"\n- \"assay\": \"immunoassay\"\n- \"tumorType\": \"NFIB\"\n\nI need to narrow these broad terms to more specific ones using the controlled terminology in the Target Schema.\n\n1. **diagnosis**: \"RASopathy\"\n   - RASopathy is a broad term referring to a group of genetic syndromes caused by mutations in genes encoding components of the RAS/MAPK pathway\n   - Looking at the enum values in the schema, RASopathies include:\n     - Neurofibromatosis type 1 (NF1)\n     - Noonan Syndrome\n     - Juvenile myelomonocytic leukemia (JMML)\n   - Since \"RASopathy\" is too broad and we need to narrow it down, but we don't have enough context to know which specific RASopathy, the most common one in the NF context would be \"Neurofibromatosis type 1\"\n   - However, looking at the options, Noonan Syndrome is explicitly listed as a RASopathy\n   - Without more context, I should probably choose \"Neurofibromatosis type 1\" as it's the most common NF-related RASopathy, but actually I don't have enough information\n   - Wait, the task says I need to narrow broad terms. If the original term is \"RASopathy\", this is indeed broad. But I need context to know which specific one. Given the context of NF research and that this is NF-related metadata, \"Neurofibromatosis type 1\" would be the most likely narrowing.\n\n2. **assay**: \"immunoassay\"\n   - \"immunoassay\" is already in the enum list exactly as written\n   - Wait, let me check: yes, \"immunoassay\" is listed in the assay enum\n   - So this one doesn't need to be changed - it's already using the exact controlled terminology\n   \n3. **tumorType**: \"NFIB\"\n   - NFIB likely stands for \"Neurofibroma\" (NF = neurofibroma, but the \"IB\" part is unclear). The schema lists several specific neurofibroma subtypes: Cutaneous, Cellular, Diffuse Infiltrating, Localized, Massive Soft Tissue, and Nodular. Without additional context about what \"IB\" signifies, I'll map this to the general \"Neurofibroma\" term.\n\nWait\u2014I need to reconsider the task. I'm supposed to narrow broad synonyms by replacing them with more specific terms from the schema. For \"assay\" \u2192 \"immunoassay\", that's already schema-compliant. For \"diagnosis\" \u2192 \"RASopathy\", this is too broad.\n\nLooking at the available options\u2014Neurofibromatosis type 1, Noonan Syndrome, and Juvenile myelomonocytic leukemia\u2014all are RASopathies. Given the NF-related context and the \"NFIB\" tumor type reference (likely neurofibroma-related), Neurofibromatosis type 1 seems most appropriate. For \"tumorType\" \u2192 \"NFIB\", without clear context, \"Neurofibroma\" is the reasonable narrowing.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"RASopathy\" \u2192 \"Neurofibromatosis type 1\" \n   - \"RASopathy\" is a broad umbrella term for genetic syndromes affecting the RAS/MAPK pathway. Narrowed to \"Neurofibromatosis type 1\" as the most common NF-related RASopathy in this context.\n\n2. **assay**: \"immunoassay\" \u2192 \"immunoassay\"\n   - No change needed. This already matches the exact controlled terminology in the Target Schema.\n\n3. **tumorType**: \"NFIB\" \u2192 \"Neurofibroma\"\n   - \"NFIB\" appears to be an abbreviation or broad code. Narrowed to \"Neurofibroma\" as the appropriate specific tumor type from the controlled vocabulary."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3055,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1322
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "immunocytochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3055,
          "output_tokens": 1322,
          "total_tokens": 4377
        }
      },
      {
        "sample_index": 7,
        "input": {
          "diagnosis": "NF",
          "assay": "medical imaging",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"conventional MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad abbreviation \"NF\" to the most common specific form of neurofibromatosis, using the exact enum value from the schema.\n\n2. **assay**: \"medical imaging\" \u2192 \"conventional MRI\" - Narrowed the very broad term \"medical imaging\" to a specific imaging modality. Conventional MRI is one of the most commonly used medical imaging techniques for neurofibromatosis and tumor assessment.\n\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\" - Corrected the capitalization to match the exact controlled terminology value \"Unknown\" from the schema's enum.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3048,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 889
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01SFUfnQKZ7Xqb3n7DEwLwK1",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad terms to more specific, exact values from the Target Schema:\n\n1. **diagnosis**: \"NF\" - This is very broad. NF typically refers to Neurofibromatosis. Looking at the enum values, I see:\n   - \"Neurofibromatosis type 1\"\n   - \"NF2-related schwannomatosis\"\n   \n   Since \"NF\" without specification is most commonly used to refer to Neurofibromatosis type 1 (NF1), but it could also mean NF2. However, when just \"NF\" is used broadly without further specification and we need to narrow it, \"Neurofibromatosis type 1\" is the most common form. But actually, if the data says \"NF\" and we don't know which type, the most appropriate narrow term from the schema would be \"Neurofibromatosis type 1\" as that's the most common, or we could use \"Unknown\". \n   \n   Actually, looking more carefully - \"NF\" is a broad term that could refer to NF1 or NF2. The schema has:\n   - \"Neurofibromatosis type 1\" (NF1)\n   - NF2 is referenced in \"NF2-related schwannomatosis\"\n   \n   Since the task is to narrow broad terms and \"NF\" most commonly refers to NF1 (which is about 96% of all NF cases), I should narrow it to \"Neurofibromatosis type 1\".\n\n2. **assay**: \"medical imaging\" - This is very broad. Looking at the enum values for imaging-related assays:\n   - \"conventional MRI\"\n   - \"diffusion MRI\"\n   - \"functional MRI\"\n   - \"structural MRI\"\n   - \"resting state functional MRI\"\n   - \"Magnetization-Prepared Rapid Gradient Echo MRI\"\n   \n   Additional imaging techniques include magnetic resonance angiography, magnetic resonance spectroscopy, ultrasound, x-ray computed tomography, and other specialized imaging methods. Given the context of NF and tumors, \"conventional MRI\" remains the most general and appropriate narrow term for medical imaging.\n\n3. **tumor**: I'll continue analyzing the specific details to narrow down this broad term.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"conventional MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad abbreviation \"NF\" to the most common specific form of neurofibromatosis, using the exact enum value from the schema.\n\n2. **assay**: \"medical imaging\" \u2192 \"conventional MRI\" - Narrowed the very broad term \"medical imaging\" to a specific imaging modality. Conventional MRI is one of the most commonly used medical imaging techniques for neurofibromatosis and tumor assessment.\n\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\" - Corrected the capitalization to match the exact controlled terminology value \"Unknown\" from the schema's enum."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3048,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 889
            }
          }
        },
        "score": 1.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 3048,
          "output_tokens": 889,
          "total_tokens": 3937
        }
      },
      {
        "sample_index": 8,
        "input": {
          "diagnosis": "neurocristopathy",
          "assay": "transcriptomics",
          "tumorType": "neurolemmoma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Schwannomatosis-NOS\",\n  \"assay\": \"transcriptomics\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: Narrowed \"neurocristopathy\" (a broad term for neural crest cell disorders) to \"Schwannomatosis-NOS\" (Not Otherwise Specified), which is a more specific diagnosis that aligns with the tumor type context.\n\n2. **assay**: \"transcriptomics\" is already a valid and appropriately specific term in the controlled terminology, so no change was needed.\n\n3. **tumorType**: Narrowed \"neurolemmoma\" (an alternative/older term) to \"Schwannoma\" (the standard, precise terminology for this tumor type).",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3056,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1046
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_014VNtosunitPkMaJ6x2Zhso",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad synonyms to more specific terms from the controlled terminology:\n\n1. **diagnosis**: \"neurocristopathy\"\n   - Neurocristopathy is a broad term referring to disorders of neural crest-derived cells\n   - Looking at the enum values, conditions like Neurofibromatosis type 1, Schwannomatosis, and related conditions are neural crest disorders\n   - \"neurocristopathy\" is too broad and could refer to multiple conditions in the list\n   - However, the most common neurocristopathies in the schema are Neurofibromatosis type 1 and various forms of Schwannomatosis\n   - Since \"neurocristopathy\" is a general term and we need to narrow it, but we don't have enough context to pick a specific one, I should look at what's most commonly meant by this term in medical literature\n   - Actually, looking at the context with tumorType \"neurolemmoma\" (which is a synonym for schwannoma), the diagnosis might be related to schwannomatosis or NF2\n   - But we're asked to narrow, and the most specific narrowing without additional context would be difficult\n   - However, \"Schwannomatosis-NOS\" (Not Otherwise Specified) might be appropriate given the tumor type is a schwannoma variant\n   - Actually, let me reconsider - \"neurocristopathy\" is indeed very broad. The task says to narrow to specific terms. Given the tumor type context (neurolemmoma/schwannoma), the most logical narrowing would be to something schwannoma-related\n   - I'll choose \"Schwannomatosis-NOS\" as it's a narrowed but still relatively general category that fits with the tumor type\n\n2. **assay**: \"transcriptomics\"\n   - This is already in the enum list as \"transcriptomics\"\n   - This is already specific enough and is a valid value in the schema\n   - I'll keep it as is\n   - \n3. **tumorType**: \"neurolemmoma\"\n   - The synonym directly maps to \"Schwannoma\" in the enum\n   - This is a straightforward narrowing from the broad term to a specific type\n   - Clearly, \"Schwannoma\" provides the precise terminology needed\n\nI'll refine my approach to ensure the most accurate mapping of terms to the controlled vocabulary.\n\nExamining the potential diagnoses, I see multiple schwannoma-related conditions. \"Schwannomatosis-NOS\" offers a balanced approach - more precise than the broad \"neurocristopathy\" while acknowledging limited contextual information. The unspecified nature suggests a cautious yet targeted diagnostic classification.\n\nIf the schwannoma lacks specific syndrome or location details, \"Sporadic Schwannoma\" emerges as a potential alternative, reflecting an isolated tumor occurrence without broader syndromic implications.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Schwannomatosis-NOS\",\n  \"assay\": \"transcriptomics\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: Narrowed \"neurocristopathy\" (a broad term for neural crest cell disorders) to \"Schwannomatosis-NOS\" (Not Otherwise Specified), which is a more specific diagnosis that aligns with the tumor type context.\n\n2. **assay**: \"transcriptomics\" is already a valid and appropriately specific term in the controlled terminology, so no change was needed.\n\n3. **tumorType**: Narrowed \"neurolemmoma\" (an alternative/older term) to \"Schwannoma\" (the standard, precise terminology for this tumor type)."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3056,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1046
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "NF2-related schwannomatosis",
          "assay": "RNA-seq",
          "tumorType": "schwannoma"
        },
        "token_usage": {
          "input_tokens": 3056,
          "output_tokens": 1046,
          "total_tokens": 4102
        }
      },
      {
        "sample_index": 9,
        "input": {
          "diagnosis": "phakomatosis",
          "assay": "viability assay",
          "tumorType": "tumor of cranial and spinal nerves"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Schwannoma\"\n}\n```",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3060,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 856
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_017FiaroX8VPELnpTvopSX5Y",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "I need to analyze the input data and narrow the broad synonyms to more specific terms from the Target Schema's controlled terminology.\n\nLet me look at each field:\n\n1. **diagnosis**: \"phakomatosis\"\n   - Phakomatosis is a broad term referring to a group of hereditary diseases characterized by tumors or malformations of the skin, nervous system, and other organs. \n   - The main phakomatoses include Neurofibromatosis (NF1, NF2), tuberous sclerosis, von Hippel-Lindau disease, and Sturge-Weber syndrome.\n   - Looking at the enum values, I see several NF-related options:\n     - \"Neurofibromatosis type 1\"\n     - \"NF2-related schwannomatosis\"\n     - \"22q-related schwannomatosis\"\n     - \"LZTR1-related schwannomatosis\"\n     - \"SMARCB1-related schwannomatosis\"\n     - \"Schwannomatosis\"\n     - \"Schwannomatosis-NEC\"\n     - \"Schwannomatosis-NOS\"\n     - \"Sporadic Schwannoma\"\n     - \"Vestibular Schwannoma\"\n   - Since the context mentions \"tumor of cranial and spinal nerves\" in tumorType, and phakomatosis in this context typically refers to neurofibromatosis, the most common and broad category would be \"Neurofibromatosis type 1\" (NF1).\n\n2. **assay**: \"viability assay\"\n   - This is a broad term. Looking at the enum, I can see several specific viability assays:\n     - \"cell viability assay\" - this is the most direct narrowing of \"viability assay\"\n     - \"3D microtissue viability\"\n     - \"in vivo PDX viability\"\n     - \"2D AlamarBlue absorbance\"\n     - \"2D AlamarBlue fluorescence\"\n   - \"cell viability assay\" seems to be the most appropriate narrow term that maintains the general meaning of viability assay.\n\n3. **tumorType**: \"tumor of cranial and spinal nerves\"\n   - This is a broad anatomical description. Looking at the enum values, tumors of cranial and spinal nerves would most commonly include:\n     - \"Schwannoma\" - tumors arising from Schwann cells in peripheral nerves\n     - \"Neurofibroma\" - tumors of nerve tissue\n     - \"Plexiform Neurofibroma\"\n     - \"Cutaneous Neurofibroma\"\n\nI'll focus on selecting the most precise terminology that captures the essential characteristics of the original broad terms while aligning with the controlled vocabulary.\n\nSchwannomas are particularly characteristic of cranial and spinal nerve tumors, especially in genetic conditions like NF2. While neurofibromas are prevalent in NF1, schwannomas more specifically represent tumors arising directly from nerve sheaths in these anatomical locations. The specificity of \"Schwannoma\" makes it the most appropriate descriptor for this broad tumor classification.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Schwannoma\"\n}\n```"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3060,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 856
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "3D microtissue viability",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3060,
          "output_tokens": 856,
          "total_tokens": 3916
        }
      }
    ],
    "metrics": {
      "total_samples": 10,
      "successful_runs": 10,
      "failed_runs": 0,
      "success_rate": 1.0,
      "average_score": 0.5,
      "min_score": 0.0,
      "max_score": 1.0,
      "num_scored": 10
    },
    "duration_seconds": 187.72662925720215,
    "token_usage": {
      "input_tokens": 30562,
      "output_tokens": 11094,
      "total_tokens": 41656
    }
  }
}